Zobrazeno 1 - 10
of 669
pro vyhledávání: '"endpoint design"'
Publikováno v:
Reproductive Health, Vol 19, Iss 1, Pp 1-11 (2022)
Plain Language Summary Endometrial adenocarcinoma (EC) is the fifth most common cancer in women worldwide, and up to 90% of EC patients are obese. Standard treatment for EC includes hysterectomy, but it leads to loss of reproductive function. This tr
Externí odkaz:
https://doaj.org/article/65120d08234a487b881ce77d851540a9
Publikováno v:
Reproductive Health. 11/4/2022, Vol. 19 Issue 1, p1-11. 11p.
Autor:
Lambert, Thomas, Nahler, Alexander, Rohla, Miklos, Reiter, Christian, Grund, Michael, Kammler, Jürgen, Blessberger, Hermann, Kypta, Alexander, Kellermair, Jörg, Schwarz, Stefan, Starnawski, Jennifer A., Lichtenauer, Michael, Weiss, Thomas W., Huber, Kurt, Steinwender, Clemens
Publikováno v:
In International Journal of Cardiology 1 October 2016 220:273-278
Publikováno v:
BMJ Open, Vol 10, Iss 2 (2020)
IntroductionProgestin therapy is the only fertility-sparing treatment option for patients with atypical endometrial hyperplasia (AEH) and endometrial cancer (EC). However, the results of three meta-analyses revealed a high remission rate, as well as
Externí odkaz:
https://doaj.org/article/75a79e5e2d534dd599866d03a4dc2bb9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
BMJ Open
BMJ Open, Vol 10, Iss 2 (2020)
BMJ Open, Vol 10, Iss 2 (2020)
IntroductionProgestin therapy is the only fertility-sparing treatment option for patients with atypical endometrial hyperplasia (AEH) and endometrial cancer (EC). However, the results of three meta-analyses revealed a high remission rate, as well as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aea03111eefe044a5ae6916451ca070
https://pubmed.ncbi.nlm.nih.gov/32114477
https://pubmed.ncbi.nlm.nih.gov/32114477
Autor:
Charu Aggarwal, Hossein Borghaei
Publikováno v:
The Oncologist
Selection of appropriate clinical endpoints for examining the efficacy of investigational agents for non‐small cell lung cancer is of vital importance in clinical trial design. This review provides an overview of the study designs of clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0963ad10f5aabfd435f5732a0ef7bd18
http://europepmc.org/articles/PMC5469580
http://europepmc.org/articles/PMC5469580
Autor:
Kurt Huber, Christian Reiter, Thomas W. Weiss, Jennifer A. Starnawski, Alexander Kypta, Clemens Steinwender, Miklos Rohla, Hermann Blessberger, Thomas Lambert, Michael Lichtenauer, Jürgen Kammler, Jörg Kellermair, Stefan Schwarz, Michael Grund, Alexander Nahler
Publikováno v:
International journal of cardiology. 220
Background Defining an adequate endpoint for renal denervation trials represents a major challenge. A high inter-individual and intra-individual variability of blood pressure levels as well as a partial or total non-adherence on antihypertensive drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e95249421e8c4a315edbdf107a03cf98
https://pubmed.ncbi.nlm.nih.gov/27390940
https://pubmed.ncbi.nlm.nih.gov/27390940
Publikováno v:
Journal of Statistical Software, Vol 89, Iss 1, Pp 1-22 (2019)
Model-based dose escalation designs have gained increasing interest due to the need for more efficient and informative Phase I trials. The wide-spread implementation of such designs has been hindered by the need for either licensing specialized comme
Externí odkaz:
https://doaj.org/article/8d87a106914f4b339677a6d575a9f33c